173 related articles for article (PubMed ID: 23644876)
1. SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt.
Zhou B; Li Y; Deng Q; Wang H; Wang Y; Cai B; Han ZG
Mol Cell Biochem; 2013 Jul; 379(1-2):191-9. PubMed ID: 23644876
[TBL] [Abstract][Full Text] [Related]
2. The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas.
Ren G; Sheng L; Liu H; Sun Y; An Y; Li Y
Med Oncol; 2015 Jul; 32(7):209. PubMed ID: 26099172
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway.
Xu Q; Liu X; Liu Z; Zhou Z; Wang Y; Tu J; Li L; Bao H; Yang L; Tu K
Mol Cancer; 2017 Jun; 16(1):103. PubMed ID: 28606154
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein 22 (HSPB8) reduces the migration of hepatocellular carcinoma cells through the suppression of the phosphoinositide 3-kinase (PI3K)/AKT pathway.
Matsushima-Nishiwaki R; Toyoda H; Takamatsu R; Yasuda E; Okuda S; Maeda A; Kaneoka Y; Yoshimi N; Kumada T; Kozawa O
Biochim Biophys Acta Mol Basis Dis; 2017 Jun; 1863(6):1629-1639. PubMed ID: 28456666
[TBL] [Abstract][Full Text] [Related]
5. FAM9C plays an anti-apoptotic role through activation of the PI3K/Akt pathway in human hepatocellular carcinoma.
Zhou JD; Shen F; Ji JS; Zheng K; Huang M; Wu JC
Oncol Rep; 2013 Sep; 30(3):1275-84. PubMed ID: 23836295
[TBL] [Abstract][Full Text] [Related]
6. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors.
Lai JP; Sandhu DS; Yu C; Moser CD; Hu C; Shire AM; Aderca I; Murphy LM; Adjei AA; Sanderson S; Roberts LR
Liver Int; 2010 Nov; 30(10):1522-8. PubMed ID: 21040406
[TBL] [Abstract][Full Text] [Related]
7. APLN promotes hepatocellular carcinoma through activating PI3K/Akt pathway and is a druggable target.
Chen H; Wong CC; Liu D; Go MYY; Wu B; Peng S; Kuang M; Wong N; Yu J
Theranostics; 2019; 9(18):5246-5260. PubMed ID: 31410213
[No Abstract] [Full Text] [Related]
8. Knockdown of Serine-Arginine Protein Kinase 1 Inhibits the Growth and Migration in Renal Cell Carcinoma Cells.
Han X; Yang J; Jia Z; Wei P; Zhang H; Lv W; Sun J; Huo Q
Oncol Res; 2017 Mar; 25(3):389-395. PubMed ID: 27662590
[TBL] [Abstract][Full Text] [Related]
9. ERCC6L promotes the progression of hepatocellular carcinoma through activating PI3K/AKT and NF-κB signaling pathway.
Chen H; Wang H; Yu X; Zhou S; Zhang Y; Wang Z; Huang S; Wang Z
BMC Cancer; 2020 Sep; 20(1):853. PubMed ID: 32891122
[TBL] [Abstract][Full Text] [Related]
10. Epithelial V-like antigen 1 promotes hepatocellular carcinoma growth and metastasis via the ERBB-PI3K-AKT pathway.
Ni Q; Chen Z; Zheng Q; Xie D; Li JJ; Cheng S; Ma X
Cancer Sci; 2020 May; 111(5):1500-1513. PubMed ID: 31997489
[TBL] [Abstract][Full Text] [Related]
11. PIM1 regulates glycolysis and promotes tumor progression in hepatocellular carcinoma.
Leung CO; Wong CC; Fan DN; Kai AK; Tung EK; Xu IM; Ng IO; Lo RC
Oncotarget; 2015 May; 6(13):10880-92. PubMed ID: 25834102
[TBL] [Abstract][Full Text] [Related]
12. SPAG5 interacts with CEP55 and exerts oncogenic activities via PI3K/AKT pathway in hepatocellular carcinoma.
Yang YF; Zhang MF; Tian QH; Fu J; Yang X; Zhang CZ; Yang H
Mol Cancer; 2018 Aug; 17(1):117. PubMed ID: 30089483
[TBL] [Abstract][Full Text] [Related]
13. MYO18B promotes hepatocellular carcinoma progression by activating PI3K/AKT/mTOR signaling pathway.
Zhang Z; Zhu J; Huang Y; Li W; Cheng H
Diagn Pathol; 2018 Nov; 13(1):85. PubMed ID: 30390677
[TBL] [Abstract][Full Text] [Related]
14. Alpha1-ACT Functions as a Tumour Suppressor in Hepatocellular Carcinoma by Inhibiting the PI3K/AKT/mTOR Signalling Pathway via Activation of PTEN.
Zhu H; Liu Q; Tang J; Xie Y; Xu X; Huang R; Zhang Y; Jin K; Sun B
Cell Physiol Biochem; 2017; 41(6):2289-2306. PubMed ID: 28456796
[TBL] [Abstract][Full Text] [Related]
15. Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway.
Hsieh YH; Hsieh SC; Lee CH; Yang SF; Cheng CW; Tang MJ; Lin CL; Lin CL; Chou RH
Oncotarget; 2015 Oct; 6(33):34859-74. PubMed ID: 26472188
[TBL] [Abstract][Full Text] [Related]
16. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
17. cPLA2α activates PI3K/AKT and inhibits Smad2/3 during epithelial-mesenchymal transition of hepatocellular carcinoma cells.
Fu H; He Y; Qi L; Chen L; Luo Y; Chen L; Li Y; Zhang N; Guo H
Cancer Lett; 2017 Sep; 403():260-270. PubMed ID: 28649002
[TBL] [Abstract][Full Text] [Related]
18. PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway.
Wang J; Sun J; Zhang N; Yang R; Li H; Zhang Y; Chen K; Kong D
Life Sci; 2019 Feb; 219():182-189. PubMed ID: 30630006
[TBL] [Abstract][Full Text] [Related]
19. NAD(P)H Quinone Dehydrogenase 1 Ablation Inhibits Activation of the Phosphoinositide 3-Kinase/Akt Serine/Threonine Kinase and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathways and Blocks Metabolic Adaptation in Hepatocellular Carcinoma.
Dimri M; Humphries A; Laknaur A; Elattar S; Lee TJ; Sharma A; Kolhe R; Satyanarayana A
Hepatology; 2020 Feb; 71(2):549-568. PubMed ID: 31215069
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of PKMYT1 is associated with autophagy inhibition and apoptosis induction and suppresses tumor progression in hepatocellular carcinoma.
Wu F; Tu C; Zhang K; Che H; Lin Q; Li Z; Zhou Q; Tang B; Yang Y; Chen M; Shao C
Biochem Biophys Res Commun; 2023 Jan; 640():173-182. PubMed ID: 36512849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
